Stifel analyst Stephen Willey said Incyte (NASDAQ: INCY) Ruxolitinib cream PDUFA extension is likely to fuel more black box warning ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE